A detailed history of Vanguard Group Inc transactions in Alvotech stock. As of the latest transaction made, Vanguard Group Inc holds 3,173,124 shares of ALVO stock, worth $37.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,173,124
Previous 3,159,749 0.42%
Holding current value
$37.8 Million
Previous $38.4 Million 1.72%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$10.76 - $12.99 $143,915 - $173,741
13,375 Added 0.42%
3,173,124 $37.8 Million
Q2 2024

Aug 13, 2024

BUY
$11.4 - $14.51 $387,201 - $492,832
33,965 Added 1.09%
3,159,749 $38.4 Million
Q1 2024

May 10, 2024

BUY
$11.36 - $17.27 $726,449 - $1.1 Million
63,948 Added 2.09%
3,125,784 $38.2 Million
Q4 2023

Feb 14, 2024

BUY
$8.55 - $11.48 $1.54 Million - $2.07 Million
180,440 Added 6.26%
3,061,836 $35.1 Million
Q3 2023

Nov 14, 2023

BUY
$8.12 - $10.07 $23.4 Million - $29 Million
2,881,396 New
2,881,396 $26.3 Million

Others Institutions Holding ALVO

About Alvotech


  • Ticker ALVO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 248,650,000
  • Market Cap $2.96B
  • Description
  • Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory condi...
More about ALVO
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.